Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cholesterol drug enters first human safety tests

NCT ID NCT06980428

First seen Nov 01, 2025 · Last updated May 26, 2026 · Updated 26 times

Summary

This study is an early-stage trial to check the safety of a new drug called AZD4954. It involves healthy volunteers and people with high cholesterol (dyslipidemia). Researchers will give single and multiple doses to see how the drug moves through the body and if it causes any side effects. The goal is to gather basic safety information, not to treat the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Glendale, California, 91206, United States

  • Research Site

    RECRUITING

    Inverness, Florida, 34452, United States

  • Research Site

    RECRUITING

    Jacksonville, Florida, 32216, United States

  • Research Site

    NOT_YET_RECRUITING

    Port Orange, Florida, 32127, United States

  • Research Site

    RECRUITING

    Brooklyn, Maryland, 21225, United States

  • Research Site

    RECRUITING

    San Antonio, Texas, 78229, United States

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.